News Sentiment

PHIO sentiment intelligence

Phio Pharmaceuticals Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 62 Constructive news tone 40 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.03 Week of 17 Jul 2026
Weighted tone 62/100

Constructive news tone

Market reaction News confirmed by price

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update

82/100 classification confidence.

Company focus 31

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+1.0% over one week, +0.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Phio Pharmaceuticals appoints dermatologist to board By Investing.com

Market Reaction

News confirmed by price

73/100 confidence

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update 82/100 classification
One-week reaction 1.0% Price digesting
Trend fit Trend inactive 0.0% over four weeks
Fair value -77.1% Below fair value
Sentiment-trend disagreement Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 18
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 31
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Stock Titan 8
Market source 7
TMX Newsfile 4
Investing.com 3
EIN Presswire 2
simplywall.st 2
Investing.com Canada 1

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 14
Balance sheet 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 40
TradingView Direct company coverage

Phio Pharmaceuticals adds R. Todd Plott to its Board, joins Governance Committee

Phio Pharmaceuticals has announced the appointment of R. Todd Plott, M.D., to its Board of Directors, effective July 20, 2026. Dr. Plott will also serve as a member of the Governance Committee. He brings over 30 years of experience in dermatologic care and innovation, including a

Tone
Positive 71/100
Event
Market update
Published
21 Jul 2026 11:39
Source
TradingView
Stock Titan Direct company coverage

More Than 30 Years in Dermatology: Phio Adds a Director

Phio Pharmaceuticals has appointed Dr. R. Todd Plott, a board-certified dermatologist and former FDA advisory committee member with over 30 years of experience, to its Board of Directors. Dr. Plott's extensive background in dermatologic care, clinical research, drug development,

Tone
Positive 74/100
Event
Market update
Published
21 Jul 2026 10:59
Source
Stock Titan
TMX Newsfile Direct company coverage

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Phio Pharmaceuticals has appointed Dr. R. Todd Plott, an experienced dermatologist and researcher, to its Board of Directors. Dr. Plott brings over 30 years of experience in dermatologic care, clinical development, and as a former FDA advisory committee member, which will be a va

Tone
Positive 66/100
Event
Market update
Published
21 Jul 2026 10:39
Source
TMX Newsfile
EIN Presswire Direct company coverage

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

Phio Pharmaceuticals has announced significant progress in protecting its proprietary INTASYL® gene silencing technology, securing multiple patent allowances and one grant in the United States, Canada, and Japan. These advancements strengthen the company's global intellectual pro

Tone
Positive 71/100
Event
Market update
Published
17 Jul 2026 13:34
Source
EIN Presswire
Stock Titan Direct company coverage

Phio Pharmaceuticals: 3 Patent Allowances, 1 Grant | PHIO Stock News

Phio Pharmaceuticals (NASDAQ: PHIO) has announced significant progress in expanding its intellectual property for its INTASYL® gene silencing technology, receiving three patent notices of allowance and one grant decision across the United States, Canada, and Japan. These new pate

Tone
Positive 72/100
Event
Market update
Published
15 Jul 2026 11:11
Source
Stock Titan
Investing.com Direct company coverage

Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan

Phio Pharmaceuticals (NASDAQ:PHIO) announced patent allowances and a grant decision in the U.S., Canada, and Japan for its INTASYL compounds, strengthening its intellectual property portfolio to 54 issued patents. The company's CEO emphasized the importance of strong patent prote

Tone
Positive 71/100
Event
Market update
Published
15 Jul 2026 11:11
Source
Investing.com
Market source Direct company coverage

Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones

Phio Pharmaceuticals has expanded its global intellectual property protection for its INTASYL® gene silencing platform with new patent milestones in the United States, Canada, and Japan. These additions bring the company's patent portfolio to 54 issued patents, covering various a

Tone
Positive 71/100
Event
Market update
Published
15 Jul 2026 11:06
Source
Market source
TradingView Direct company coverage

Enterprise value to EBITDA forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO

This page from TradingView provides financial information for Phio Pharmaceuticals Corp. under the NASDAQ:PHIO ticker. It focuses on the enterprise value to EBITDA forward metric for the company. The page also includes general market information, tools, and community links from t

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 09:40
Source
TradingView
Intellectia AI Direct company coverage

PHIO PE Ratio & Valuation, Is PHIO Overvalued

This article analyzes the valuation of Phio Pharmaceuticals Corp (PHIO), noting it is currently in the "Fair zone" based on its forward PS ratio compared to its five-year average. It details current P/B ratios, Free Cash Flow yields, and compares PHIO's valuation metrics, such as

Tone
Neutral 50/100
Event
Balance sheet
Published
02 Jul 2026 18:10
Source
Intellectia AI
TradingView Direct company coverage

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series on June 30, 2026. CEO Robert Bitterman will present an overview of the company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for treating

Tone
Positive 63/100
Event
Market update
Published
30 Jun 2026 18:42
Source
TradingView
Investing.com South Africa Direct company coverage

Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock By Investing.com

Phio Pharmaceuticals CEO Robert Bitterman recently purchased 10,000 shares of the company's common stock for a total of $9,900. This insider transaction occurred on June 26, 2026, with shares priced at $0.99 each. The stock is currently trading near its 52-week low, and an Invest

Tone
Positive 66/100
Event
Market update
Published
30 Jun 2026 04:10
Source
Investing.com South Africa
Stock Titan Direct company coverage

Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, reported an open-market purchase of 10,000 shares of common stock at $0.99 per share on June 26, 2026. Following this transaction, Bitterman directly owns 421,421 shares, including those underlying un

Tone
Positive 71/100
Event
Market update
Published
30 Jun 2026 03:40
Source
Stock Titan
TradingView Direct company coverage

PHIO: PH-762 achieved strong safety and efficacy, with INTASYL poised for broader clinical impact

Phio Pharmaceuticals Corp. (PHIO) announced strong safety and efficacy results for PH-762 in a phase I-B trial, leveraging their INTASYL platform. The company plans a new clinical trial next year and is actively seeking funding to expand indications, as highlighted in a recent fi

Tone
Positive 71/100
Event
Earnings
Published
29 Jun 2026 18:10
Source
TradingView
EIN Presswire Direct company coverage

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

Phio Pharmaceuticals has reached a significant milestone with the commencement of commercial-scale cGMP manufacturing of its lead candidate, PH-762, for its INTASYL® siRNA platform. This production, handled by Nitto Denko Avecia, Inc., follows the completion of Phio's Phase 1b do

Tone
Positive 73/100
Event
Market update
Published
26 Jun 2026 15:10
Source
EIN Presswire
Stock Titan Direct company coverage

Phio CEO to pitch INTASYL cancer platform in June 30 webcast

Phio Pharmaceuticals will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow on June 30, 2026, where CEO Robert Bitterman will present the company's INTASYL siRNA platform and lead candidate PH-762 for skin cancers. PH-762 is an INTASYL compound th

Tone
Positive 70/100
Event
Market update
Published
26 Jun 2026 11:10
Source
Stock Titan
Quartr Direct company coverage

Phio Pharmaceuticals (PHIO) Life Sciences Virtual Investor Forum Summary

Phio Pharmaceuticals provided a summary of their Life Sciences Virtual Investor Forum, highlighting their INTASYL platform which uses gene silencing to enhance immune cell effectiveness against cancer, specifically targeting cutaneous squamous cell carcinoma. Their PH-762 drug ca

Tone
Positive 72/100
Event
Market update
Published
26 Jun 2026 01:10
Source
Quartr
TradingView Direct company coverage

PHIO Forecast — Price Target — Prediction for 2027

This article provides a forecast for Phio Pharmaceuticals Corp. (PHIO), including a price target of $14.00 from one analyst. It details the company's current stock performance, market capitalization, upcoming earnings date (August 6, 2026), and past financial results, highlightin

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:40
Source
TradingView
TradingView Direct company coverage

Phio Pharmaceuticals Corp. Actuals & Estimates (MUN:44R1)

This article provides an overview of Phio Pharmaceuticals Corp. (MUN:44R1) financial actuals, estimates, and analyst forecasts. It details historical stock performance, upcoming earnings reports, and key financial figures like EPS and revenue, noting that the company does not pay

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:10
Source
TradingView
TMX Newsfile Direct company coverage

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026

Phio Pharmaceuticals is holding a virtual fireside chat on June 29, 2026, with Force Family Office to discuss how siRNA therapy can revolutionize cancer treatment. CEO Robert Bitterman and Dr. James Cardia will highlight their proprietary INTASYL® gene silencing technology, speci

Tone
Positive 77/100
Event
Market update
Published
25 Jun 2026 10:40
Source
TMX Newsfile
The National Law Review Direct company coverage

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026

Phio Pharmaceuticals will participate in the Life Sciences Investor Forum on June 24-25, 2026. CEO Robert Bitterman will present the company's INTASYL® siRNA platform and lead clinical candidate PH-762 for various skin cancers. The event will include a live presentation, Q&A sess

Tone
Positive 67/100
Event
Market update
Published
24 Jun 2026 13:40
Source
The National Law Review
Investing.com Direct company coverage

Phio Pharmaceuticals begins commercial-scale production of PH-762

Phio Pharmaceuticals has initiated commercial-scale cGMP production of its drug substance PH-762 at Nitto Denko Avecia, Inc. This marks a significant step towards the next phase of development for their lead clinical compound, PH-762, which is designed to silence the PD-1 gene fo

Tone
Positive 72/100
Event
Market update
Published
24 Jun 2026 12:12
Source
Investing.com
Stock Titan Direct company coverage

Phio’s PH-762 clears a manufacturing step toward its next trial

Phio Pharmaceuticals announced that Nitto Denko Avecia has begun commercial-scale cGMP production of PH-762 drug substance, a significant milestone for its lead candidate. This new supply is essential for supporting an upcoming clinical trial as Phio advances its intratumoral pro

Tone
Positive 75/100
Event
Macro sensitivity
Published
24 Jun 2026 11:10
Source
Stock Titan
Stock Titan Direct company coverage

Phio CEO to pitch INTASYL cancer platform at investor forum June 25

Phio Pharmaceuticals (NASDAQ: PHIO) CEO Robert Bitterman will present the company's INTASYL gene silencing technology and lead clinical candidate PH-762 for cutaneous carcinomas at the Life Sciences Investor Forum on June 25, 2026. The presentation will be followed by a live Q&A

Tone
Positive 64/100
Event
Market update
Published
21 Jun 2026 05:41
Source
Stock Titan